# Thyroid 2020 Case Scenarios Answer Sheets

|  |
| --- |
| **Case Scenario 1** |
| Primary Site | C73.9 | Histology  | 8260 | Behavior | 3 |
| MP Rule | M18 | H Rule | H23 |  |  |
| Clinical Grade | 9 | Pathological Grade | 9 | Post-therapy Grade |  |
| **Stage/ Prognostic Factors** |
| Age | 48 | Tumor Size Clin | 999 |
| Clinical T |  | Tumor Size Path | 007 |
| Clinical T Suffix |  | Tumor Size Summary | 007 |
| Clinical N |  | Regional Nodes Pos | 00 |
| Clinical N Suffix |  | Regional Nodes Ex | 03 |
| Clinical M |  |  |  |
| Clinical Stage | 99 | EOD Ext | 100 |
|  |  | EOD LN | 000 |
| Pathological T | pT1a | EOD Mets | 00 |
| Pathological T Suffix | (m) |  |  |
| Pathological N | pN0a | Summary Stage 2018 | 1-Localized |
| Pathological N Suffix |  |  |  |
| Pathological M | cM0 |  |  |
| Pathological Stage | 1 |  |  |
| **Treatment** |
| Diagnostic Staging Procedure | 00 | **Systemic Therapy Codes** |  |
| **Surgery Codes** |  | Chemotherapy | 00 |
| Surgical Procedure of Primary Site | 50 | Hormone Therapy | 01 |
| Scope of Regional Lymph Node Surgery | 4 | Immunotherapy | 00 |
| Surgical Procedure/ Other Site | 0 | Hematologic Transplant/ Endocrine Procedure | 00 |
|  |  | Systemic/Surgery Sequence | 3 |
| Radiation |
| Radiation Primary Tx Volume | 00 | Dose per Fraction |  |
| Radiation to Primary LN’s |  | Number of Fractions |  |
| Radiation Tx Modality | 00 | Total Dose |  |
| Radiation Planning Technique |  | Number of Phases |  |

|  |
| --- |
| **Case Scenario 2a** |
| Primary Site | C73.9 | Histology  | 8345 | Behavior | 3 |
| MP Rule | M17 | H Rule | H23 |  |  |
| Clinical Grade | 9 | Pathological Grade | 9 | Post-therapy Grade |  |
| **Stage/ Prognostic Factors** |
| Age | 60 | Tumor Size Clin | 010 |
| Clinical T | cT1a | Tumor Size Path | 007 |
| Clinical T Suffix | (s) | Tumor Size Summary | 007 |
| Clinical N | cN0b | Regional Nodes Pos | 00 |
| Clinical N Suffix |  | Regional Nodes Ex | 05 |
| Clinical M | cM0 |  |  |
| Clinical Stage | 1 | EOD Ext | 100 |
|  |  | EOD LN | 000 |
| Pathological T | pT1a | EOD Mets | 00 |
| Pathological T Suffix | (m) |  |  |
| Pathological N | pN0a | Summary Stage 2018 | 1-Localized |
| Pathological N Suffix |  |  |  |
| Pathological M | cM0 |  |  |
| Pathological Stage | 1 |  |  |
| **Treatment** |
| Diagnostic Staging Procedure | 02 | **Systemic Therapy Codes** |  |
| **Surgery Codes** |  | Chemotherapy | 00 |
| Surgical Procedure of Primary Site | 50 | Hormone Therapy | 01 |
| Scope of Regional Lymph Node Surgery | 5 | Immunotherapy | 00 |
| Surgical Procedure/ Other Site | 0 | Hematologic Transplant/ Endocrine Procedure | 00 |
|  |  | Systemic/Surgery Sequence | 3 |
| Radiation |
| Radiation Primary Tx Volume | 98 (other) | Dose per Fraction | 999998 |
| Radiation to Primary LN’s | 00 | Number of Fractions | 1 |
| Radiation Tx Modality | 13 (RAI) | Total Dose | 9999998 |
| Radiation Planning Technique | 88 | Number of Phases | 1 |

|  |
| --- |
| **Case Scenario 2b** |
| Primary Site | C73.9 | Histology  | 8260 | Behavior | 3 |
| MP Rule | M17 | H Rule | H11 |  |  |
| Clinical Grade | 9 | Pathological Grade | 9 | Post-therapy Grade |  |
| **Stage/ Prognostic Factors** |
| Age | 60 | Tumor Size Clin | 999 |
| Clinical T |  | Tumor Size Path | 001 |
| Clinical T Suffix |  | Tumor Size Summary | 001 |
| Clinical N |  | Regional Nodes Pos | 00 |
| Clinical N Suffix |  | Regional Nodes Ex | 05 |
| Clinical M |  |  |  |
| Clinical Stage | 99 | EOD Ext | 100 |
|  |  | EOD LN | 000 |
| Pathological T | pT1a | EOD Mets | 00 |
| Pathological T Suffix | (s) |  |  |
| Pathological N | pN0a | Summary Stage 2018 | 1-Localized |
| Pathological N Suffix |  |  |  |
| Pathological M | cM0 |  |  |
| Pathological Stage | 1 |  |  |
| **Treatment** |
| Diagnostic Staging Procedure | 00 | **Systemic Therapy Codes** |  |
| **Surgery Codes** |  | Chemotherapy | 00 |
| Surgical Procedure of Primary Site | 50 | Hormone Therapy | 01 |
| Scope of Regional Lymph Node Surgery | 5 | Immunotherapy | 00 |
| Surgical Procedure/ Other Site | 0 | Hematologic Transplant/ Endocrine Procedure | 00 |
|  |  | Systemic/Surgery Sequence | 3 |
| Radiation |
| Radiation Primary Tx Volume | 98 (other) | Dose per Fraction | 999998 |
| Radiation to Primary LN’s | 00 | Number of Fractions | 1 |
| Radiation Tx Modality | 13 (RAI) | Total Dose | 9999998 |
| Radiation Planning Technique | 88 | Number of Phases | 1 |

|  |
| --- |
| **Case Scenario 3** |
| Primary Site | C73.9 | Histology  | 8021 | Behavior | 3 |
| MP Rule | M2 | H Rule | H11 |  |  |
| Clinical Grade | 4 | Pathological Grade | 4 | Post-therapy Grade |  |
| **Stage/ Prognostic Factors** |
| Age | 58 | Tumor Size Clin | 060 |
| Clinical T | cT3b | Tumor Size Path | 088 |
| Clinical T Suffix | (s) | Tumor Size Summary | 088 |
| Clinical N | cN1a | Regional Nodes Pos | 02 |
| Clinical N Suffix | (f) | Regional Nodes Ex | 15 |
| Clinical M | cM0 |  |  |
| Clinical Stage | 4B | EOD Ext | 400 |
|  |  | EOD LN | 300 |
| Pathological T | pT4a | EOD Mets | 00 |
| Pathological T Suffix | (s) |  |  |
| Pathological N | pN1a | Summary Stage 2018 | 4 |
| Pathological N Suffix |  |  |  |
| Pathological M | cM0 |  |  |
| Pathological Stage | 4B |  |  |
| **Treatment** |
| Diagnostic Staging Procedure | 00 | **Systemic Therapy Codes** |  |
| **Surgery Codes** |  | Chemotherapy | 03 |
| Surgical Procedure of Primary Site | 23 | Hormone Therapy | 01 |
| Scope of Regional Lymph Node Surgery | 5 | Immunotherapy | 00 |
| Surgical Procedure/ Other Site | 0 | Hematologic Transplant/ Endocrine Procedure | 0 |
|  |  | Systemic/Surgery Sequence | 3 |
| Radiation |
| Radiation Primary Tx Volume | 00 | Dose per Fraction |  |
| Radiation to Primary LN’s |  | Number of Fractions |  |
| Radiation Tx Modality | 00 | Total Dose |  |
| Radiation Planning Technique |  | Number of Phases |  |

|  |
| --- |
| **Case Scenario 4** |
| Primary Site | C73.9 | Histology  | 8337 | Behavior | 3 |
| MP Rule | M2 | H Rule | H11 |  |  |
| Clinical Grade | 9 | Pathological Grade | 3 | Post-therapy Grade |  |
| **Stage/ Prognostic Factors** |
| Age | 70 | Tumor Size Clin | 045 |
| Clinical T | cT3a | Tumor Size Path | 045 |
| Clinical T Suffix | (s) | Tumor Size Summary | 045 |
| Clinical N | cN0b | Regional Nodes Pos | 98 |
| Clinical N Suffix |  | Regional Nodes Ex | 00 |
| Clinical M | pM1 |  |  |
| Clinical Stage | 4B | EOD Ext | 200 |
|  |  | EOD LN | 050 |
| Pathological T | pT3a | EOD Mets | 70 |
| Pathological T Suffix | (s) |  |  |
| Pathological N | pNX | Summary Stage 2018 | 7 distant mets |
| Pathological N Suffix |  |  |  |
| Pathological M | pM1 |  |  |
| Pathological Stage | 4B |  |  |
| **Treatment** |
| Diagnostic Staging Procedure | 00 | **Systemic Therapy Codes** |  |
| **Surgery Codes** |  | Chemotherapy | 00 |
| Surgical Procedure of Primary Site | 50 | Hormone Therapy | 01 |
| Scope of Regional Lymph Node Surgery | 0 | Immunotherapy | 00 |
| Surgical Procedure/ Other Site | 0 | Hematologic Transplant/ Endocrine Procedure | 0 |
|  |  | Systemic/Surgery Sequence | 3 |
| Radiation |
| Radiation Primary Tx Volume | 98 (other) | Dose per Fraction | 999998 |
| Radiation to Primary LN’s | 00 | Number of Fractions | 1 |
| Radiation Tx Modality | 13 (RAI) | Total Dose | 9999998 |
| Radiation Planning Technique | 88 | Number of Phases | 1 |